Malignant Hyperthermia

Malignant Hyperthermia (MH) is a rare, inherited musculoskeletal syndrome that presents as a hypermetabolic reaction triggered by exposure to volatile anesthetic gases (e.g., desflurane, enflurane, halothane, sevoflurane) or the depolarizing muscle relaxant, succinylcholine. The signs of MH include muscle rigidity, rapid heart rate, high body temperature, muscle breakdown and increased acid content.

CRNAs, student registered nurse anesthetists, other clinicians, and facility administrators are encouraged to review available resources and assess their knowledge, preparedness, and training to periodically affirm the team’s readiness for an MH crisis. Anesthesia professionals may be the first to recognize the onset of an MH crisis, but a coordinated team response is vital in the effective treatment and management of MH.

The Malignant Hyperthermia Association of the United States (MHAUS) has developed numerous resources and guidance for clinicians and patients to promote optimum care and scientific understanding of MH and related disorders. Jacqueline Sumanis, DNAP, CRNA is a member of the MHAUS Board of Directors.

AANA Resources

Testing for MH

Stocking Dantolene

MH Drills

Preoperative Recommendations

Intraoperative Recommendations

Postoperative Recommendations

Patient Transfer

The North American Malignant Hyperthermia Registry of MHAUS


​​​The resources on this page may incorporate or summarize views, guidelines, or recommendations of third parties. Such material is assembled and presented in good faith, but does not necessarily reflect the views of the AANA. Links to third-party websites are inserted for informational purposes and do not constitute endorsement of the material on those sites, or of any associated organization.

MHAUS Emergency
24 hour hotline:


Connect with MHAUS